Literature DB >> 2091333

The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria.

S M Mansor1, T E Taylor, C S McGrath, G Edwards, S A Ward, J J Wirima, M E Molyneux.   

Abstract

The safety and kinetics of intramuscular quinine (10 mg salt/kg every 8 h for 3 doses) were assessed in Malawian children suffering from uncomplicated falciparum malaria, who were unable to take oral antimalarial drugs. Treatment was completed with oral pyrimethamine-sulfadoxine. The mean (+/- SD) peak plasma quinine concentration after the first injection was 9.0 (+/- 2.3) micrograms/ml, at 1.1 (+/- 0.7) h. Mean plasma concentrations increased further after the second and third doses to a maximum of 11.5 (+/- 2.6) micrograms/ml at 16.1 (+/- 3.2) h. No hypotension, hypoglycaemia or electrocardiographic abnormalities developed during quinine treatment. These results provide further evidence for the safety of intramuscular quinine in children with moderately severe malaria. Plasma concentrations of alpha 1-acid glycoprotein (AGP) were higher, and the degree of protein binding of quinine was greater, in acute malaria than in convalescence. There was a significant correlation between AGP concentration and the fraction of plasma quinine bound to plasma protein. These findings suggest a role for AGP in the binding of quinine in plasma in vivo and are of interest since unbound quinine is responsible for both the efficacy and toxicity of the drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2091333     DOI: 10.1016/0035-9203(90)90007-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  14 in total

1.  Population pharmacokinetics of intramuscular quinine in children with severe malaria.

Authors:  S Krishna; N V Nagaraja; T Planche; T Agbenyega; G Bedo-Addo; D Ansong; A Owusu-Ofori; A L Shroads; G Henderson; A Hutson; H Derendorf; P W Stacpoole
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Pharmacology and parasitology: integrating experimental methods and approaches to falciparum malaria.

Authors:  P A Winstanley; W M Watkins
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

3.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria.

Authors:  K Silamut; P Molunto; M Ho; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

4.  Effect of dose size on the pharmacokinetics of orally administered quinine.

Authors:  A Sowunmi; L A Salako
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

5.  Disposition of quinine in plasma, red blood cells and saliva after oral and intravenous administration to healthy adult Africans.

Authors:  L A Salako; A Sowunmi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

7.  Pharmacokinetics of quinine in African patients with acute falciparum malaria.

Authors:  C P Babalola; O O Bolaji; F A Ogunbona; A Sowunmi; O Walker
Journal:  Pharm World Sci       Date:  1998-06

8.  Effect of Plasmodium falciparum malaria infection on the plasma concentration of alpha 1-acid glycoprotein and the binding of quinine in Malawian children.

Authors:  S M Mansor; M E Molyneux; T E Taylor; S A Ward; J J Wirima; G Edwards
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

9.  Disposition of quinine in rats with induced renal failure.

Authors:  C O Onyeji; P A Dixon; N C Ugwu
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

10.  Packaged treatment for first-line care in cerebral malaria and meningitis.

Authors:  T R Cullinan; C Pieterick
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.